College of Basic medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, P.R. China.
Medicine (Baltimore). 2021 Feb 5;100(5):e24210. doi: 10.1097/MD.0000000000024210.
With the development of social economy, people's lives are improving day by day. Chronic diseases represented by diabetes have gradually entered people's field of vision. At present, about 415 million people in the world suffer from diabetes, of which more than 90% are Type 2 diabetic mellitus (T2DM), which causes severe physical and mental pain to patients and their families, and also imposes a huge burden on the health care system. Animal experiments and clinical studies both show that Gegen Qinlian Decoction (GQD) cannot only reduce the blood glucose of T2DM, but also improve the islet function of patients, reduce the insulin resistance index and insulin secretion index, and have no adverse reactions. Therefore, we designed this protocol to evaluate the effect of GQD on clinical Prognosis and islet function for T2DM.
This review was conducted from January 1, 2000 to October 1, 2020, sourced from the Cochrane Library, Pubmed, Excerpt Medica Database, Science Direct, World Health Organization, International Clinical Trials Registration Platform, Web of Science, Chinese Biomedical Literature, the China National Knowledge Infrastructure Database, Wanfang Database, Chinese Scientific Journal Database. In this study clinical randomized controlled trial is used and we set inclusion criteria and exclusion criteria for screening. The primary outcomes include Fasting plasma glucose,2 h plasma glucose, Hemoglobin A1c, fasting plasma insulin, insulin resistance index and insulin secretion index. Review Manager 5.3 software will be used for data analysis.
This study will provide the systematic evidence of the effect of GQD on Clinical Prognosis and islet function for T2DM.
The findings of this meta-analysis will provide evidence to evaluate the effect of GQD on Clinical Prognosis and islet function for type 2 diabetic mellitus.
INPLASY2020110083.
随着社会经济的发展，人们的生活水平日益提高。以糖尿病为代表的慢性病逐渐进入人们的视野。目前，全球约有 4.15 亿人患有糖尿病，其中 90%以上为 2 型糖尿病（T2DM），给患者及其家庭带来了严重的身心痛苦，也给医疗保健系统带来了巨大负担。动物实验和临床研究均表明，葛根芩连汤（GQD）不仅能降低 T2DM 患者的血糖，还能改善患者的胰岛功能，降低胰岛素抵抗指数和胰岛素分泌指数，且无不良反应。因此，我们设计了本方案来评价 GQD 对 T2DM 患者临床预后及胰岛功能的影响。
本综述于 2000 年 1 月 1 日至 2020 年 10 月 1 日进行，数据来源于 Cochrane 图书馆、PubMed、Excerpt Medica 数据库、Science Direct、世界卫生组织、国际临床试验注册平台、Web of Science、中国生物医学文献数据库、中国国家知识基础设施数据库、万方数据库、中国科学引文数据库。本研究采用临床随机对照试验，设定了纳入和排除标准进行筛选。主要结局指标包括空腹血糖、餐后 2 小时血糖、糖化血红蛋白、空腹胰岛素、胰岛素抵抗指数和胰岛素分泌指数。采用 Review Manager 5.3 软件进行数据分析。
本研究将为 GQD 对 T2DM 患者临床预后及胰岛功能的影响提供系统证据。
本荟萃分析的结果将为评价 GQD 对 2 型糖尿病患者临床预后及胰岛功能的影响提供证据。
INPLASY 注册号：INPLASY2020110083。
